Influence of myocardial infarction on changes in the expression of angiotensin type 1 receptor in the rat prostate

Folia Histochemica et Cytobiologica

Volumn 49, Issue 3, 2011, Pages 497-503

  Piastowska Ciesielska, Agnieszka W ^a   Drobnik, Jacek ^a   Zarzyńska, Joanna ^b   Domińska, Kamila ^a   Russell, John A ^c   Ochedalski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiotensin receptor; Myocardial infarction; Prostate; Rat

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 1B RECEPTOR; ANGIOTENSIN 2 RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; GEL ELECTROPHORESIS; HEART INFARCTION; HEART INFARCTION SIZE; HISTOPATHOLOGY; MALE; NONHUMAN; OPTICAL DENSITY; PROSTATE; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

RATTUS; RATTUS NORVEGICUS;

EID: 84856801103     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0070     Document Type: Article

References (47)

1. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293-299.
2. Zhu YC, Zhu YZ, Lu N, Wang MJ, Wang YX, Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol. 2003;30:911-918.
3. Chow L, Rezmann L, Catt KJ et al. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol. 2009;302:219-229.
4. Leung PS, Sernia C. The renin-angiotensin system and male reproduction: new functions for old hormones. J Mol Endocrinol. 2003;30:263-270.
5. O'Mahony OA, Barker S, Puddefoot JR, Vinson GP. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology. 2005;146:392-398.
6. Chow L, Rezmann L, Catt KJ et al. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol. 2009;302:219-229.
7. Milik E, Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Dobruch J, Morton M, Koperski L. Upregulation of angiotensin AT1a receptors mRNA in the heart and renal medulla after myocardial infarction in rats. J Physiol Pharmacol. 2006;57:375-388.
8. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol. 2006;33:1269-1274.
9. Pretorius L, Owen KL, Jennings GL, McMullen JR. Promoting physiological hypertrophy in the failing heart. Clin Exp Pharmacol Physiol. 2008;35:438-441.
10. Greco S, Muscella A, Elia MG et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 2003;196:370-377.
11. McWhinney CD, Dostal D, Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol. 1998;30:751-761.
12. Haulica I, Bild W, Serban DN. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst. 2005;6:121-131.
13. Unger T, Chung O, Csikos T et al. Angiotensin receptors. J Hypertens Suppl 1996;14:S95-103.
14. Uemura H, Ishiguro H, Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem. 2006;6:835-844.
15. Natarajan R, Kathuria S, Lanting L, Gonzales N, Nadler J. Differential short- and long-term effects of insulin on ANG II action in human adrenal glomerulosa cells. Am J Physiol. 1995;268:E100-E106.
16. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123:255-278.
17. Huang BS, Ahmad M, Tan J, Leenen FH. Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;297:H968-H975.
18. Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol. 2008;15:19-26.
19. Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, Fabiani ME. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology. 2001;142:1349-1356.
20. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res. 2002;35:1001-1015.
21. Baker KM, Kumar R. Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol. 2006;291:C995-1001.
22. Earp HS, Huckle WR, Dawson TL, Li X, Graves LM, Dy R. Angiotensin II activates at least two tyrosine kinases in rat liver epithelial cells. Separation of the major calcium-regulated tyrosine kinase from p125FAK. J Biol Chem. 1995;270: 28440-28447.
23. Vinson GP, Ho MM, Puddefoot JR. The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems. Mol Med Today. 1995;1:35-39.
24. Cheng HF, Becker BN, Burns KD, Harris RC. Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1995;95:2012-2019.
25. Dinh DT, Frauman AG, Somers GR et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol. 2002; 196:213-219.
26. Uemura H, Ishiguro H, Nakaigawa N et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2:1139-1147.
27. Uemura H, Ishiguro H, Nagashima Y et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005;4:1699-1709.
28. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets. 2005;5:307-323.
29. Wennemuth G, Aumuller G. Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br J Pharmacol. 2005;144:3-10.
30. Chow L, Rezmann L, Imamura K et al. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate. 2008; 68:651-660.
31. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferatoractivated receptor gamma ligand like action. Prostate. 2007;67:924-932.
32. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002;62:6021-6025.
33. Drobnik J, Karbownik-Lewinska M, Szczepanowska A et al. Regulatory influence of melatonin on collagen accumulation in the infarcted heart scar. J Pineal Res. 2008;45:285-290.
34. Busche S, Gallinat S, Bohle RM et al. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase- polymerase chain reaction study. Am J Pathol. 2000;157:605-611.
35. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation. 1995; 92:3105-3112.
36. Schunkert H, Ingelfinger JR, Hirsch AT et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest. 1992;90:1523-1529.
37. Zhu YZ, Zhu YC, Li J et al. Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. J Renin Angiotensin Aldosterone Syst. 2000;1:257-262.
38. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000;97:931-936.
39. Tan J, Wang H, Leenen FH. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol. 2004;286:1665-1671.
40. Hoshino K, Ishiguro H, Teranishi JI et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 2010;71:964-975.
41. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495:197-200.
42. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer. 2001;85:1396-1399.
43. +ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol. 2002;173:315-323.
44. Suganuma T, Ino K, Shibata K et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11:2686-2694.
45. Marsigliante S, Resta L, Muscella A, Vinson GP, Marzullo A, Storelli C. AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett. 1996;110:19-27.
46. Kikkawa F, Mizuno M, Shibata K et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol. 2004;190:1258-1263.
47. Arnold JT, Gray NE, Jacobowitz K et al. Human prostate stromal cells stimulate increased PSA production in DHEAtreated prostate cancer epithelial cells. J Steroid Biochem Mol Biol. 2008;111:240-246.